Skip to main content
. Author manuscript; available in PMC: 2018 Oct 9.
Published in final edited form as: Nat Genet. 2018 Apr 9;50(4):538–548. doi: 10.1038/s41588-018-0092-1

Table 2. TWAS genes with association to schizophrenia and chromatin phenotypes.

42 genes (including 7 genes at novel loci, highlighted with a [*]) had a significant TWAS association with SCZ and chromatin phenotypes. For each significant TWAS association with SCZ, the number of significant genechromatin associations (FWER 5% among TWAS gene-mark associations, by Bonforroni correction) are reported. In the middle columns ‘.’ represents genes that were not heritable in the study and therefore not TWAS-associated. In the right columns ‘.’ represents no identified association; genes with no chromatin associations are not shown. Top panel shows results from genes, with TSS listed as position; bottom panel shows results from splicing events in CMC with exon-exon junction listed as position (details in Supplementary Table 18). The minority of loci without subsequent evidence of colocalziation of molecular phenotype with SCZ are indicated with (see Supplementary Table 3 for full numerical results).

Gene Chr Position TWAS P-value
Associated marks
YFS/blood MET/adipose NTR/blood CMC/brain DHS H3K27AC H3K4ME1 H3K4ME3 PU1 RPB2
RERE 1 8,483,747 4e-07 2e-06 2e-06 . . . . . . 3
SLC45A1 1 8,378,144 . . . 4e-08 . . . . . 1
MAP7D1* 1 36,621,565 6e-04 . 1e-06 . . . . . . 1
MED8 1 43,855,483 5e-01 . . 2e-06 . . 1 . . .
ANP32E 1 150,207,026 . . 1e-08 . . . . 1 . .
MRPS21 1 150,266,261 3e-06 3e-03 6e-03 2e-02 . . 1 . . .
RFWD2* 1 176,176,380 4e-06 . . . . . 1 . . .
C2orf69 2 200,775,978 . 6e-10 . . . . . 1 . .
GLT8D1 3 52,737,714 . . 5e-08 3e-08 . 1 . . . .
GLYCTK 3 52,321,835 2e-08 . . . . 1 . . . .
GNL3 3 52,719,935 7e-09 6e-07 . 5e-02 . . . 1 . .
NEK4 3 52,804,965 . . . 2e-09 . . . 1 . .
NT5DC2 3 52,567,793 6e-06 6e-06 . 7e-01 . 1 . 1 . .
PPM1M 3 52,279,808 2e-07 2e-07 . 2e-03 . 1 . . . .
TMEM110 3 52,931,597 1e-02 4e-01 1e-08 6e-06 . 1 1 2 . .
PCCB 3 135,969,166 1e-08 1e-10 . 3e-10 1 . 3 . . .
RP11-53O19.3 5 44,826,178 . 6e-06 . . . . 1 . . .
DND1 5 140,053,171 . 8e-07 1e-02 . . 1 . 1 . .
IK 5 140,027,383 4e-06 1e-06 . 5e-05 . 1 . 1 . .
NDUFA2 5 140,027,370 2e-06 . . 4e-06 . 1 . 2 . .
PCDHA2 5 140,174,443 . . . 7e-06 . 1 . 1 . .
ZMAT2 5 140,080,031 5e-06 1e-03 . 3e-06 . . . 1 . .
AS3MT 10 104,629,209 . 6e-08 7e-09 1e-05 . 1 . . . .
MPHOSPH9 12 123,717,785 4e-09 1e-05 . 2e-08 . 1 . . 1 .
KIAA0391* 14 35,591,526 7e-01 2e-07 5e-01 . . 2 1 . . .
PPP2R3C* 14 35,591,748 6e-05 1e-01 3e-06 2e-02 . 2 2 . . .
MAPK3 16 30,134,630 5e-05 . . 1e-06 . 1 . . . 1
GFOD2 16 67,753,273 . . 6e-07 2e-05 . 1 . 2 . .
TSNAXIP1 16 67,840,780 . . . 2e-06 . . 1 2 . .
DUS2L 16 68,038,024 1e-06 . 3e-06 4e-04 . . . 2 . .
PRMT7 16 68,344,876 1e-05 8e-04 . 8e-06 . . 1 1 . .
GRAP* 17 18,950,336 . . 5e-07 . . . . . . 1
RNF112* 17 19,314,490 8e-06 . . . . . . . . 1
ACTR5 20 37,377,096 2e-07 2e-04 . 7e-01 1 . 1 . . .
CBR3 21 37,507,262 6e-03 2e-03 2e-06 5e-04 1 . 2 . . .

CMC/brain splicing
TBC1D5 3 17,255,862 - 17,279,655 . . . 3e-06 . . 1 . . .
NEK4 3 52,800,010 - 52,800,194 . . . 1e-06 . . 1 . . .
CCDC90B 11 82,985,783 - 82,991,184 . . . 3e-07 . 1 . . . .
SBNO1 12 123,821,038 - 123,825,535 . . . 4e-10 . . . . 1 .
KLC1 14 104,145,855 - 104,151,323 . . . 7e-12 . . 1 1 . .
RTN1* 14 60,074,210 - 60,193,637 . . . 1e-06 . . 1 . . .
TAOK2 16 29,997,825 - 29,998,165 . . . 4e-06 . . . . . 1
PPP4C 16 30,094,168 - 30,094,715 . . . 2e-06 . . . . . 1
*

Novel, not overlapping 108 PGC SCZ GWAS loci.

No significant SCZ colocalization posterior in any reference (exlucding chromatin features in YRI).